Table 4.6.
Developed inhaled technological forms of insulin
| Company | Product | Clinical phase |
|---|---|---|
| Pfizer | EXUBERA® | Withdrawal due to low sales |
| Novo Nordisk | AERx® | Interruption in clinical phase III |
| Eli Lilly and Company and Alkermes Inc. | AIR® Insulin | Completion of the clinical phase III |
| MannKind Corporation | Technosphere® Insulin System | Clinical phase III (USA, Europe, Latin America) |
| Baxter | Recombinant human insulin inhalation powder (RHIIP) based on Baxter’s proprietary PROMAXX formulation technology | Clinical phase I |
| Ventura and MicroDose Technologies Inc. | QDose insulin | Encouraging results of inhaled insulin will be announced. Prospective clinical studies |